The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV
Lisa O’Brien, Nathan Shaffer, Nalinee Sangrujee & Taiwo O Abimbola
Volume 92, Number 3, March 2014, 162-170
Table 1. Model inputs – and their sources – for study of the incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV
|Median postpartum CD4+ cell count, cells/µl|
|Lower: 350–500||425||Ekouevi, 2012
|Higher: > 500||613||Ekouevi, 2012
|CD4+ cell count for ART eligibility, cells/µl||≤ 350||WHO, 2010
|Monthly decline in CD4+ cell count postpartum, cells/µl|
|Breastfeeding woman||3.2 (1.5, 4.9)a||Otieno, 2007
|Non-breastfeeding woman||4.4 (2.7, 6.0)a||Otieno, 2007
|Cost per patient per year, US$|
|TDF + 3TC + EFV||167.31||WHO, GPRM, 2011
|Co-trimoxazole, routine clinical monitoring and laboratory services||211.81||Menzies, 2011
|First 12 months on ART|
|Non-ARV drugs, routine clinical monitoring and laboratory services||378.54||Menzies, 2011
|Maintained on ART|
|Non-ARV drugs, routine clinical monitoring and laboratory services||246.42||Menzies, 2011
3TC, lamivudine; ART, antiretroviral therapy; ARV, antiretroviral; EFV, efavirenz; TDF, tenofovir; US$, United States dollars; WHO, World Health Organization.
a Values in parentheses were used to simulate a slow and a rapid monthly decline in CD4+ cell count.
b Breastfeeding and non-breastfeeding women.